HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment ...
HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
After receiving word late last month that the FDA would not be issuing a 510(k) clearance to its cable-free electrocardiogram ...
HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac ...
The FDA clearance unlocks multiple growth initiatives for HeartBeam. The company plans a limited commercial launch in Q1 2026 ...
TipRanks on MSN
HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal
Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, ...
NITDA has issued a security advisory, warning users about newly discovered vulnerabilities in OpenAI’s ChatGPT models.
After spending a small fortune on Christmas presents, the last thing you want is to get caught short by missing batteries or ...
HeartBeam's 1st synthesized 12-lead ECG cleared by FDA, enabling cable-free at-home arrhythmia assessment with launch set for 2026.
Today’s outages hit harder, so smart redundancy — backed by good policies, automation and testing — is the only way to keep ...
Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback